Literature DB >> 8281849

Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils.

H Allgayer1, S Rang, U Klotz, P Böhne, J Retey, W Kruis, R Gugler.   

Abstract

Reactive oxygen species such as superoxide radicals have been proposed to play an important role in the pathogenesis of inflammatory bowel disease. Some of the antiinflammatory actions of aminosalicylates have been ascribed to their capability to scavenge superoxide radicals directly or to inhibit its production in stimulated neutrophils. However, as a controversy still exists with regard to the precise mechanisms of inhibition and the metabolism within inflammatory cells, we compared scavenger properties of 5-aminosalicylic acid, 4-aminosalicylic acid, N-acetyl aminosalicylic acid, olsalazine, and benzalazine in systems with defined superoxide radical generation such as the dimethyl sulfoxide-NaOH and the potassium superoxide system. We also studied possible inhibition of the superoxide production following different stimuli of the respiratory burst in neutrophils and investigated the uptake and potential metabolism (N-acetylation) of 5-aminosalicylic acid in lipopolysaccharide-primed and resting neutrophils. We found that 5-aminosalicylic acid and 4-aminosalicylic acid had defined scavenger properties in the dimethyl sulfoxide-NaOH or potassium superoxide systems, respectively, whereas compounds with a modified aminophenolic structure had no effects. At the cellular level, 5-aminosalicylic acid inhibited phorbol myristate acetate (100 ng/ml)-activated superoxide generation to 82.3 +/- 9.3%, the formylmethionyl leucyl peptide (10(-5) M) to 61.0 +/- 6.8%, and the NaF (20 mM)-stimulated production to 32.3 +/- 3.2% (mean +/- SD, P < 0.01). The actions of the other drugs were less pronounced. Almost identical retention times (Rt = 11.2 min) of 3H-labeled phorbol myristate acetate in the presence and absence of 5-aminosalicylic acid revealed no in vitro interactions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8281849     DOI: 10.1007/BF02090074

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Activation of NADPH oxidase in human neutrophils. Synergism between fMLP and the neutrophil products PAF and LTB4.

Authors:  B Dewald; M Baggiolini
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

2.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

3.  Sulfasalazine and its anti-inflammatory metabolite, 5-aminosalicylic acid: effect on arachidonic acid metabolism in human neutrophils, and free radical scavenging.

Authors:  I Ahnfelt-Rønne; O H Nielsen; K Bukhave; J Elmgreen
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1987

4.  Inhibition of antibody secretion by 5-aminosalicylic acid.

Authors:  R P MacDermott; S R Schloemann; M J Bertovich; G S Nash; M Peters; W F Stenson
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

5.  Mechanisms for luminol-augmented chemiluminescence from neutrophils induced by leukotriene B4 and N-formyl-methionyl-leucyl-phenylalanine.

Authors:  H Gyllenhammar
Journal:  Photochem Photobiol       Date:  1989-02       Impact factor: 3.421

6.  Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography.

Authors:  E Brendel; I Meineke; D Witsch; M Zschunke
Journal:  J Chromatogr       Date:  1987-01-09

7.  Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease.

Authors:  T P Mulder; H W Verspaget; A R Janssens; P A de Bruin; A S Peña; C B Lamers
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

8.  Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.

Authors:  K Lauritsen; J Hansen; M Ryde; J Rask-Madsen
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

9.  A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid.

Authors:  H Allgayer; W F Stenson
Journal:  Immunopharmacology       Date:  1988 Jan-Feb

10.  Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme.

Authors:  L A Guthrie; L C McPhail; P M Henson; R B Johnston
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

View more
  5 in total

1.  5-Aminosalicylic acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro.

Authors:  J Kanski; C Lauderback; D A Butterfield
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages.

Authors:  A Vazquez-Torres; J Jones-Carson; E Balish
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

3.  Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers.

Authors:  M E McAlindon; A F Muller; B Filipowicz; C J Hawkey
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

4.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

5.  Flavonoids and 5-aminosalicylic acid inhibit the formation of neutrophil extracellular traps.

Authors:  Tina Kirchner; Eva Hermann; Sonja Möller; Matthias Klinger; Werner Solbach; Tamás Laskay; Martina Behnen
Journal:  Mediators Inflamm       Date:  2013-12-07       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.